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ABSTRACT Gram-negative bacteria in the order Rickettsiales have an obligate intra-
cellular growth requirement, and some species cause human diseases such as ty-
phus and spotted fever. The bacteria have evolved a dependence on essential nutri-
ents and metabolites from the host cell as a consequence of extensive genome
reduction. However, it remains largely unknown which nutrients they acquire and
whether their metabolic dependency can be exploited therapeutically. Here, we de-
scribe a genetic rewiring of bacterial isoprenoid biosynthetic pathways in the Rickett-
siales that has resulted from reductive genome evolution. Furthermore, we investi-
gated whether the spotted fever group Rickettsia species Rickettsia parkeri scavenges
isoprenoid precursors directly from the host. Using targeted mass spectrometry, we
found that infection caused decreases in host isoprenoid products and concomitant
increases in bacterial isoprenoid metabolites. Additionally, we report that treatment
of infected cells with statins, which inhibit host isoprenoid synthesis, prohibited bac-
terial growth. We show that growth inhibition correlates with changes in bacterial
size and shape that mimic those caused by antibiotics that inhibit peptidoglycan
biosynthesis, suggesting that statins lead to an inhibition of cell wall synthesis. Alto-
gether, our results describe a potential Achilles’ heel of obligate intracellular patho-
gens that can potentially be exploited with host-targeted therapeutics that interfere
with metabolic pathways required for bacterial growth.
IMPORTANCE Obligate intracellular pathogens, which include viruses as well as cer-
tain bacteria and eukaryotes, are a subset of infectious microbes that are metaboli-
cally dependent on and unable to grow outside an infected host cell because they
have lost or lack essential biosynthetic pathways. In this study, we describe a
metabolic dependency of the bacterial pathogen Rickettsia parkeri on host iso-
prenoid molecules that are used in the biosynthesis of downstream products, in-
cluding cholesterol, steroid hormones, and heme. Bacteria make products from
isoprenoids, such as an essential lipid carrier for making the bacterial cell wall.
We show that bacterial metabolic dependency can represent a potential Achilles’
heel and that inhibiting host isoprenoid biosynthesis with the FDA-approved sta-
tin class of drugs inhibits bacterial growth by interfering with the integrity of the
cell wall. This work supports the potential to treat infections by obligate intracel-
lular pathogens through inhibition of host biosynthetic pathways that are sus-
ceptible to parasitism.
KEYWORDS Rickettsia, isoprenoids, metabolic parasitism
Gram-negative Alphaproteobacteria in the family Rickettsiaceae, which include thegenera Rickettsia and Orientia, are obligate intracellular bacteria that can cause
human diseases, including spotted fever (spotted fever group [SFG] Rickettsia), typhus
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(typhus group [TG] Rickettsia), and scrub typhus (Orientia species) (1). These bacteria are
transmitted to mammals by arthropod vectors such as fleas, ticks, and mites. Although
most pathogenic species cause moderately severe illnesses, in some cases infections
can be fatal, even after treatment with first-line antibiotics (2). We study the SFG species
Rickettsia parkeri, which causes an eschar at the site of the tick bite and symptoms that
include fever, malaise, nausea, headaches, and an occasional rash (3, 4).
Upon invasion of host cells, Rickettsia species quickly escape the primary vacuole
into the host cell cytoplasm, where the bacteria grow and proliferate. Obligate growth
inside host cells has resulted in genome size reduction, and Rickettsia species have
relatively small genomes of 1.1 to 1.5 Mbp (5–9) that encode a reduced number of
proteins (1,273 predicted proteins in R. parkeri; NCBI reference sequence NC_017044.1).
This typically correlates with the loss of genes encoding components of metabolic
biosynthetic pathways, together with the requirement to scavenge essential metabo-
lites from the host (5, 8).
One essential class of metabolites are the isoprenoids (also known as terpenoids),
which are derived from simple five-carbon isoprene units that are assembled to make
thousands of different molecules. The biosynthesis of the central isoprene precursor
molecule, isopentenyl pyrophosphate (IPP), and its isomer, dimethylallyl diphosphate
(DMAPP), occurs through two distinct pathways: the mevalonate (MEV) pathway (pre-
dominantly in archaea, Gram-positive bacteria, and animals) or the 2-C-methyl-D-
erythritol 4-phosphate (MEP) pathway (primarily in Gram-negative bacteria) (Fig. 1). In
bacteria, isoprenoid biosynthesis produces vital products such as bactoprenols, which
are essential building blocks for peptidoglycan (PG), chlorophylls in cyanobacteria, and
the O-antigen of lipopolysaccharides (LPS), as well as ubiquinone and menaquinone,
which are involved in the electron transport chain (10). In mammalian cells, isoprenoid
biosynthesis produces a larger variety of products, including cholesterol, ubiquinone,
steroid hormones, prenylated proteins, heme, and vitamin K (11).
Although the isoprenoid biosynthetic pathway is essential to most pathogens, its
components are missing from certain obligate pathogens including Mycoplasma spe-
cies (12) and the protozoan parasite Cryptosporidium (13). A recent bioinformatic
analysis by Driscoll et al. (14) demonstrated that genes encoding the upstream enzymes
from the MEV and MEP pathways that are required to make IPP and DMAPP are also
missing in Rickettsia species, with the exception of the idi gene encoding the central
isoprenoid pathway enzyme isopentenyl diphosphate isomerase (IDI), which catalyzes
the reversible conversion of IPP to DMAPP (15). Furthermore, this analysis revealed that
a trans,trans-farnesyl diphosphate (FPP) synthase involved in the synthesis of larger
terpenoids, required for the generation of geranyl diphosphate (GPP) and FPP, is
likewise missing within the Rickettsia species genomes (14). Because Rickettsia species
have access to metabolites in the host cytoplasm, Driscoll et al. hypothesized that
Rickettsia species may steal IPP, DMAPP, and FPP, altering the flux of host-derived
isoprenoid precursors to initiate downstream bacterial isoprenoid biogenesis. The
downstream enzymes required to utilize these short-chained isoprenoid precursors for
ubiquinone biosynthesis and PG biosynthesis are encoded in Rickettsia species ge-
nomes.
In this study, we explore the evolutionary changes that occurred within the order
Rickettsiales with respect to the presence of genes encoding components of the
isoprenoid biosynthetic pathway. We also show that bacterial infection results in
depletion of host isoprenoid products and the synthesis of bacterial isoprenoid prod-
ucts. Furthermore, we use a chemical genetic approach to reveal that inhibition of host
isoprenoid biosynthesis by statin treatment prevents bacterial growth and alters bac-
terial shape. Our results suggest that the host MEV pathway serves as the upstream
source of isoprene units for the synthesis of bacterial bactoprenols and ubiquinone and
that inhibition of the host MEV pathway by statins may represent a promising avenue
for host-directed therapeutics to limit Rickettsia species infection.
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RESULTS
The isoprenoid biosynthesis pathway is under evolutionary flux in the order
Rickettsiales. We first sought to determine the evolutionary conservation of the
isoprenoid biosynthesis pathway in the order Rickettsiales. We analyzed six major
genera of the order and assessed the presence or absence of genes encoding upstream
or downstream components of the MEP pathway as well as the central isoprenoid
pathway enzyme, IDI (Fig. 2A; see also Table S1 in the supplemental material). We
confirmed that the Rickettsia (14) and Orientia lineages lack the genes encoding
upstream MEP pathway enzymes but retain those encoding the downstream pathway
components, whereas the other genera contained the full complement of MEP pathway
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FIG 1 Generalized MEV and MEP pathways leading to downstream isoprenoid products. The green arrows indicate
the presence of annotated enzymes encoded in the R. parkeri genome. The gray arrows indicate the absence of
annotated enzymes encoded in the R. parkeri genome. The orange arrow indicates the presence of the IDI enzyme
from the host genome. The yellow background denotes the upstream isoprenoid pathway, whereas the blue
denotes the downstream isoprenoid pathway. The central black arrow and white question mark denote the
possible presence of transporters for isoprenoids from the host into the bacteria. Arrows with double hash marks
indicate multiple enzymatic steps. Statin drugs inhibit the activity of HMG-CoA reductase and the formation of
mevalonate of the MEV pathway. Fosmidomycin is an inhibitor of DXP reductoisomerase of the MEP pathway.
Alendronate sodium hydrate is an inhibitor of farnesyl diphosphate synthase. D-Cycloserine (DCS) is an inhibitor of
D-alanine racemase and D-alanine-D-alanine ligase.
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genes. None have MEV pathway genes, but the idi gene is present in Rickettsia species.
The absence of upstream MEP pathway genes suggests that Rickettsia species must
scavenge MEV/MEP pathway intermediates (IPP, DMAPP and/or FPP) (Fig. 1) from the
host cell.
Additionally, the idi gene is present only in the Rickettsia lineage and not in the
Orientia lineage. A previous report suggested that the idi gene in Rickettsia species was
acquired by horizontal gene transfer (14). To further investigate this possibility, we
examined the genomic locus surrounding the idi gene in the genome of the R. parkeri
strain Portsmouth (Fig. 2B). We found many surrounding genes that were associated
with conjugal transfer functions, such as transposases and pili. Furthermore, there are
nine surrounding pseudogenes with premature stop codons, suggesting that this
region is in flux and may be in the process of undergoing genomic reduction. To further
test this hypothesis, we performed a whole-genome alignment between R. parkeri and
the closely related yet more pathogenic species Rickettsia rickettsii. Interestingly, we
found that the two genomes were highly syntenic, with the exception of a 65-kb region
containing the idi gene (Fig. 2C, region in lime green and idi gene in purple) that is
inverted between the two species and that in the R. rickettsii genome contains a 33.5-kb
deletion (Fig. 2C orange highlighted region; Table S2). These observations suggest that
the locus surrounding the idi gene was acquired by horizontal gene transfer (in
agreement with previous phylogeny estimation [14] and with reports of similar genome
rearrangements in Rickettsia species [16]) and is still under evolutionary pressure to
retain the idi gene while simultaneously undergoing continuing reduction.
R. parkeri infection results in depletion of host isoprenoid products and accu-
mulation of bacterial isoprenoid products. To test whether R. parkeri scavenges host
isoprenoids to make bacterial products, we measured the presence and abundance of
host and bacterial isoprenoid-derived metabolites by liquid chromatography tandem
mass spectrometry (LC-MS/MS). Confluent infected and mock-infected cultures of
African green monkey kidney epithelial Vero cell cultures were incubated for 4 days,
collected, and then extracted for lipid metabolites. For host isoprenoids, we monitored
cholesterol, total cholesteryl esters, cholesteryl oleate, and ubiquinone-10 using single-
reaction monitoring (SRM)-based LC-MS/MS methods (Fig. 3). We observed a statisti-
cally significant, approximately 2-fold, decrease in total cholesteryl esters and choles-
teryl oleate in the infected samples compared to levels in uninfected samples. These
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FIG 3 Targeted mass spectrometry of bacterial and host isoprenoids. Shown is a graph of the internal
standard equivalent levels of host and bacterial isoprenoids at 4 dpi. Four technical replicates were done.
Error bars represent standard deviations. Statistical comparisons were done by an unpaired Student’s t
test (ns, not significant; **, P 0.01; ***, P 0.001; ****, P 0.0001, for results compared to those with
the controls).
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products are generally understood to be the storage units of cholesterol packaged in
intracellular lipid droplets (17). In contrast, we saw no change in cholesterol or
ubiquinone-10. Thus, infection results in the depletion of isoprenoid-derived storage
forms of cholesterol.
For bacterial isoprenoids, we measured bactoprenols, including the isoprenoid
products C55 pyrophosphate (C55-PP) and C55 phosphate (C55-P) (based on targeting for
the [M-H] parent masses because there were no authentic standards available). C55-PP
is initially produced by a dedicated prenyltransferase, UppS, and must be dephospho-
rylated to C55-P to act as a lipid carrier (18). We also measured bacterial ubiquinone,
ubiquinone-8, which contains an 8-prenyl subunit tail, in contrast with the human
version ubiquinone-10, which contains 10 prenyl subunits (Fig. 3) (19, 20). We observed
an 4-fold increase in both C55-PP and C55-P in infected cells compared to levels in
uninfected cells (values were normalized to internal standards [21, 22]). We did not,
however, find significant differences in bacterial ubiquinone (ubiquinone-8) levels,
possibly due to the presence of ubiquinone-8 intermediates from the host cell
ubiquinone-10 biosynthesis pathway. These results suggest that bacterial isoprenoid
products, primarily bactoprenols, accumulate during R. parkeri infection. Collectively,
the depletion of host isoprenoid products and accumulation of bacterial isoprenoid
products, even in the absence of a bacterial isoprenoid synthesis pathway, suggest that
isoprenoids are scavenged from the host by R. parkeri.
Chemical inhibition of the host mevalonate pathway inhibits bacterial growth.
To determine whether host isoprenoids are necessary for bacterial growth, we sought
to inhibit the host mevalonate pathway and reduce the pool of available host IPP,
DMAPP, and FPP. We used statins, a class of drugs that block the activity of 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase (Fig. 1). A previous report showed
that preincubation of Rickettsia conorii-infected mouse L929 fibroblast cells with the
statin lovastatin caused a reduction in R. conorii plaque size, which was interpreted to
result from a reduction in cholesterol-dependent adherence of bacteria to host cells
(23). To bypass possible effects of statins on bacterial adherence and invasion, we
allowed infection of Vero cells to proceed for 2 h to allow for maximal bacterial
adherence/invasion (24) and then, using untreated cells and cells treated with various
concentrations of the statin pitavastatin, measured bacterial numbers using an R.
parkeri-specific quantitative PCR (qPCR) endpoint assay (Fig. 4A). We observed a2-log
reduction in bacterial growth with increasing pitavastatin concentrations. To ensure
that statin inhibition of bacterial growth was dependent on HMG-CoA reductase
inhibition by pitavastatin and not on secondary effects of the drug, we tested whether
the downstream product of HMG-CoA reductase, mevalonate, could rescue this growth
inhibition. Indeed, cotreatment with 400 M mevalonate and pitavastatin rescued
bacterial growth (Fig. 4A).
To further assess the importance of the MEV pathway, we generated dose-response
curves for the effects of lovastatin and pitavastatin, which are chemically distinct, on R.
parkeri growth using a 96-well qPCR endpoint assay. We observed a dose-dependent
inhibition of bacterial growth with lovastatin (50% effective concentration [EC50],
2.0 M) and even more robust inhibition with pitavastatin (EC50, 0.5 M) (Fig. 4B). The
effect of statins on bacterial growth was not due to host cell death as treatment of
uninfected cells throughout the dose-response range caused no significant loss of cell
viability as measured by lactate dehydrogenase release (Fig. S1A) (although subcyto-
toxic concentrations of pitavastatin have been shown to alter cellular phenotypes such
as the proportion of cells in different stages of the cell cycle, oxidant-induced apoptosis,
or viability of different cancel cell lines [25–27]). Furthermore, host cells remained
adherent throughout the dose-response range although there was an apparent de-
crease in cell-cell contact at concentrations of lovastatin and pitavastatin greater than
the EC50 for bacterial growth inhibition (Fig. S1B). Together, these data indicate that the
host MEV pathway is critical for R. parkeri growth.
To further test that bacterial growth is dependent on a complex integration of
the host and pathogen isoprenoid pathways (depicted in Fig. 1), we tested for
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dose-dependent growth inhibition using additional inhibitors of MEV and MEP pathway
enzymes (Fig. 4B). Fosmidomycin, which specifically inhibits 1-deoxy-D-xylulose
5-phosphate (DXP) reductoisomerase, a key enzyme in the bacterial MEP pathway,
caused no inhibition of bacterial growth at up to 100 M. Alendronate sodium, a
specific inhibitor of host farnesyl diphosphate (FPP) synthase, caused approximately
50% growth inhibition. This further suggests that R. parkeri growth is independent of
bacterial isoprenoid production and partially dependent on FPP from the host.
Finally, we tested the antibiotic tetracycline, which is used as a first-line treatment
for Rickettsia species infection and targets protein synthesis, or D-cycloserine, which
blocks the PG biosynthesis pathway that also requires isoprenoid biosynthesis prod-
ucts. Tetracycline inhibited growth, with an EC50 of 0.7 M, consistent with MIC values
for SFG rickettsiae of 0.06 to 0.25 g/ml (0.1 to 0.5 M) (28). D-Cycloserine also caused
a dose-dependent inhibition of R. parkeri growth, with an EC50 of 56 M, consistent
with effects on Rickettsia prowazekii (29) and with MIC values for Escherichia coli K-12
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FIG 4 Chemical inhibition and rescue of R. parkeri growth. (A) Graph of R. parkeri genome copy numbers
in the presence of various concentrations of pitavastatin, without or with mevalonate. Two independent
biological replicates were performed, but four technical replicates from a single experiment are shown
for simplicity. Error bars represent standard deviations. Statistical comparisons were done by an unpaired
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Dose-dependent growth inhibition of R. parkeri in the presence of the indicated drugs targeting the MEV
or MEP pathway enzymes or of tetracycline, normalized to that of a no-drug control. Fosmidomycin and
alendronate failed to generate fit curves.
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(MIC of 30 g/ml, or 290 M) (30) and Mycobacterium tuberculosis (MIC of 15 g/ml, or
150 M) (31). Taken together, the results of chemical inhibition assays support the
notion that Rickettsia species are dependent on the upstream host MEV pathway but
not the upstream MEP pathway. Furthermore, they are susceptible to inhibition of PG
biosynthesis.
Statin treatment causes bacterial shape defects that mimic those caused by
peptidoglycan-targeting antibiotics. We sought to further assess the effect of statin
treatment on bacterial physiology. Limiting the availability of isoprenoids is predicted
to result in reduced PG synthesis. Though Rickettsia species (28), like other Gram-
negative bacteria (32), are generally resistant to PG-targeted antibiotics, one study
showed that high concentrations of penicillin produced spheroplasts (33), a type of
L-form bacteria that have defective PG cell walls and take on a spherical shape (34).
Therefore, we sought to measure whether statin inhibition of the host MEV pathway
altered bacterial shape in a similar manner to inhibition of PG synthesis. To this end, we
performed immunofluorescence microscopy on 96-well plates of infected cells at 3 days
postinfection (dpi) to track the alterations of bacterial shape in response to dose-
dependent application of statins, D-cycloserine, or tetracycline as a control. We per-
formed automated image analysis using CellProfiler (35) and measured features of
bacterial cell shape. We determined that two shape measurements, area and eccen-
tricity (circle  0; rod/line  1), accounted for most of the shape alterations seen in the
concentration ranges between the EC50 and EC100. In D-cycloserine-treated cells, there
was a dose-dependent increase in area and decrease in eccentricity as bacteria became
more circular and less rod shaped (Fig. 5A and B). In cells treated with either lovastatin
or pitavastatin, similar changes in area and eccentricity were seen along the dose-
response curve. In contrast, upon treatment with tetracycline, we found little change in
the bacterial area although there was a general decrease in eccentricity.
Upon comparison of shape at the EC100 of each drug with that of the untreated
control, we observed a significant increase in bacterial area and decrease in eccentricity
in cells treated with D-cycloserine, lovastatin, and pitavastatin (Fig. 5C). For tetracycline,
we found no significant differences in area or eccentricity compared to those of the
untreated control group, likely because tetracycline does not directly interfere with cell
wall biosynthesis. Thus, growth inhibition by statins causes bacterial shape defects that
are similar to those caused by D-cycloserine, suggesting a shared mechanism of
bacterial growth inhibition resulting from targeting host isoprenoid and bacterial PG
synthesis pathways.
DISCUSSION
Obligate intracellular pathogens such as Rickettsia species are dependent upon
nutrients and metabolites from their host cells as a consequence of reductive genome
evolution (5, 6, 14). This suggests the possibility that this metabolic dependency
represents an Achilles’ heel in the host-pathogen relationship and that these pathogens
could be sensitive to changes in host cell nutrient and metabolite levels. If metabolite
availability is limited by the host or by extrinsic pressures, such as chemical inhibition
of a host biosynthetic pathway, pathogen growth should also be reduced. Here, we
report the reduction of R. parkeri replication when the host isoprenoid pathway is
inhibited with statins. This growth inhibition correlates with changes in bacterial shape
that are consistent with defects in cell wall biosynthesis. Our results suggest that statins
interfere with Rickettsia species scavenging of host isoprenoids used for downstream
biosynthetic pathways such as peptidoglycan biosynthesis, measured in this study.
We observed that the isoprenoid biosynthesis pathway is under evolutionary flux in
the order Rickettsiales, with the Rickettsia and Orientia lineages having lost genes
encoding the upstream components of the MEP pathway and Rickettsia species having
gained the idi gene, consistent with previous findings (14). Through our understanding
of reductive genome evolution and gene acquisition in prokaryotes (5, 6, 8, 36), we can
surmise a most parsimonious order of loss and gain of isoprenoid biosynthetic pathway
genes in the Rickettsiales. We propose that the common ancestor of the Rickettsia and
Ahyong et al.
November/December 2019 Volume 4 Issue 6 e00536-19 msphere.asm.org 8
1 10 100 1000 10000
0.0
0.2
0.4
0.6
0.8
0.5
0.6
0.7
0.8
0.9
1.0
[lovastatin] μM
[tetracycline] μM[D-cycloserine] μM
[pitavastatin] μM
eccentricity
arbitrary units
eccentricity
arbitrary units
eccentricity
arbitrary units
eccentricity
arbitrary units
0.01 0.1 1 10 100
0.0
0.2
0.4
0.6
0.8
0.5
0.6
0.7
0.8
0.9
1.0
0.1 1 10 100 1000
0.0
0.2
0.4
0.6
0.8
0.5
0.6
0.7
0.8
0.9
1.0
0.001 0.01 0.1 1 10
0.0
0.2
0.4
0.6
0.8
0.5
0.6
0.7
0.8
0.9
1.0
ar
ea
 μ
m
2
ar
ea
 μ
m
2
ar
ea
 μ
m
2
ec
ce
nt
ric
ity
ar
bi
tra
ry
 u
ni
ts
ar
ea
 μ
m
2
ar
ea
 μ
m
2
area
area EC100 eccentricity EC100
eccentricity
A.
B.
C.
lovastatin
pitavastatin
D-cycloserine
tetracycline
[drug]nd
0.0
0.2
0.4
0.6
0.4
0.6
0.8
nd dcs tet lov pit nd dcs tet lov pit
ns ns** **** **** *** **** ***
FIG 5 Shape and size measurements of R. parkeri bacteria under pressure from different drugs. (A) Representative bacterial cells from
the EC curve drug concentrations from panel B. Scale bar, 1 m. (B) Dose-dependent changes in area and eccentricity of R. parkeri
bacterial cells under drug treatment with lovastatin, pitavastatin, tetracycline, or D-cycloserine. Each measurement is the mean of at least
40 individual bacterial cells, except for concentrations of D-cycloserine at 250 M, where most bacterial cells were lysed and fewer
measurements were possible (for 500 M D-cycloserine, n 22; for 1,000 M D-cycloserine, n 18; for 2,000 M D-cycloserine, n 13).
Error bars represent the 95% confidence interval. (C) Graphs plotting area and eccentricity measurements at the EC100 values calculated
from the data shown in Fig. 4B and matched to measurements from panel A. Regions shaded in yellow are the calculated values of EC50
to EC100 from the data shown in Fig. 4B. Graphs show the mean of the sample set, and error bars represent the 95% confidence interval.
Statistical comparisons were done by one-way ANOVA of results for all drug-treated samples compared to results for the no-drug (nd)
sample set (ns, not significant; **, P 0.01; ***, P 0.001; ****, P 0.0001). dcs, D-cycloserine; tet, tetracycline; lov, lovastatin; pit,
pitavastatin.
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Orientia lineages, which inhabit the host cell cytoplasm, may have gained the ability to
scavenge IPP, DMAPP, and/or FPP from the cytoplasm by acquisition of a gene
encoding a transporter that moves these highly charged pyrophosphate molecules into
the bacterial cell. There is evidence for the presence of such transporters in plants,
bacteria, and protozoan parasites although their molecular identities remain uncertain
(37–39). Furthermore, previous studies in R. prowazekii have implicated metabolite
transporters that allow the acquisition of triose phosphates from the host cell (40, 41).
Gaining an IPP transporter would have enabled the loss of the upstream MEP pathway
genes to reduce the bacterial genome and reduce fitness costs of pathway redundancy.
Subsequently, the idi gene was gained in the Rickettsia lineage, which may reflect a
need for additional DMAPP beyond that acquired from the host MEV pathway. In
contrast, Ehrlichia, Anaplasma,Wolbachia, and Neorickettsia lineages, which grow within
a membrane-bound vacuole, may not have sufficient access to host IPP and/or DMAPP
and therefore have retained the entire MEP pathway.
We also found evidence of metabolic parasitism of host isoprenoids by R. parkeri. In
particular, infected host cells became depleted of isoprenoid-derived storage forms of
cholesterol, total cholesteryl esters, and choleteryl oleate, perhaps to balance free
cholesterol levels. Curiously, we did not find differences in host or bacterial ubiquinone
levels during infection, perhaps due to host compensation for reduced ubiquinone in
response to infection. An additional complication of this metabolite analysis is the fact
that ubiquinone-8 is an on-pathway intermediate in the synthesis of host ubiquinone-
10, possibly masking our ability to distinguish changes in either host or bacterial
ubiquinones in infected versus uninfected cells by mass spectrometry. Whether Rick-
ettsia species also scavenge downstream host isoprenoid products such as cholesterol,
as observed for other bacteria such as M. tuberculosis and Chlamydia trachomatis
(42–44), remains to be determined. Furthermore, R. parkeri produces downstream
isoprenoid products even though it lacks genes for the upstream components of the
MEP pathway. This metabolic parasitism suggests that inhibition of host isoprenoid
biosynthesis should reduce the ability of the bacteria to synthesize bacterial isoprenoid
products.
In keeping with this prediction, we found that statins, which inhibit host HMG-CoA
reductase, halt R. parkeri growth. Previous work had established an ability of statins to
limit rickettsial plaque size (23), but the mechanism of inhibition was not explored in
detail. It was suggested that statins might inhibit bacterial adherence to and/or
invasion of host cells based on previous studies that had found a role for cholesterol in
these processes (45, 46). Our work reveals an effect of statins on intracellular bacterial
growth, downstream of adherence/invasion, as well as an effect on bacterial morphol-
ogy that mirrors that which is caused by the cell wall synthesis inhibitor D-cycloserine.
Whether statins have a bactericidal or bacteriostatic effect remains to be determined,
but we observed morphological evidence of bacterial lysis at higher concentrations of
statins, similar to lysis effects seen with D-cycloserine treatment but not with tetracy-
cline treatment. These observations led us to conclude that statins inhibit bacterial
growth by reducing host metabolite availability for production of bacterial products
required for PG biosynthesis, leading to lethal defects in the bacterial cell wall. Future
studies are also needed to determine if there are additional effects of statins on
bacterial O-antigen and ubiquinone-8.
Whether statins can be effective at preventing or treating human Rickettsia species
infections remains to be determined. Although statins are well tolerated in humans, we
have limited understanding of the concentrations that would inhibit bacterial growth
without causing toxicity. It is also unclear if statins cause the same degree of bacterial
growth inhibition in different rickettsial target cell types in vivo. Additional studies in
animal models will shed light on the future promise of statins as a prophylaxis or
treatment for rickettsial infections. Currently, cases of rickettsial diseases are effectively
treated with tetracyclines although there are reported cases of tetracycline-resistant
scrub typhus (47, 48), and tetracycline treatment is contraindicated for pregnant
women and young children (49). Statins are also contraindicated for pregnant women
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although in children (50) pitavastatin has been found to be both efficacious and safe
(51). Because a limited number of antibiotics are effective in treating rickettsial infec-
tions (28), host-targeted therapeutics would be useful additions to treatment regimens.
Furthermore, targeting host biosynthesis of essential metabolites may limit the devel-
opment of antibiotic resistance.
Beyond the scope of rickettsial infections, this study supports the hypothesis of
using host-targeted therapeutics for a wide variety of infectious microbes, including
viruses, bacteria, fungi, and parasites. Similar to R. parkeri, the parasite Cryptosporidium
parvum lacks the canonical protozoan isoprenoid pathway and has been shown to be
sensitive to statins (52). Interestingly, the facultative intracellular protozoan parasite
Toxoplasma gondii, which encodes the MEP isoprenoid pathway within a membrane-
bound organelle called the apicoplast, has been shown to be sensitive to statins when
the parasite is intracellular (53, 54), suggesting that host metabolite scavenging is still
advantageous for pathogens with intact pathways. In the future, bioinformatic analyses
may identify other intracellular bacteria that have incomplete upstream isoprenoid
pathways and intact downstream isoprenoid pathways and thus may also be sensitive
to statins. Furthermore, Rickettsia species and other parasites may be sensitive to
chemical inhibition of other host metabolic pathways. Layering our knowledge of
FDA-approved compounds that target host biosynthetic pathways onto predicted
metabolic pathways hijacked by pathogens may therefore enable the systematic
identification of drug classes that could be repurposed as antibiotics.
MATERIALS AND METHODS
Reagents. Hoechst 33342 (B2261), D-cycloserine (C6880), tetracycline (T7660), fosmidomycin (F8682),
mevalonate (M4667), and alendronate sodium hydrate (A4978) were obtained from Sigma-Aldrich.
ProLong Gold Antifade (P36930), goat anti-mouse Alexa-488 secondary antibody (R37120), 0.25%
trypsin-EDTA-phenol red (25200056), and a Dynamo HS SYBR green qPCR kit (F-410L) were obtained
from ThermoFisher Scientific. Pitavastatin (494210) and lovastatin InSolution (4381875) were from Fisher
Scientific. Anti-Rickettsia 14-13 antibody was generously provided by Ted Hackstadt, NIH/NIAID Rocky
Mountain Laboratories (55).
Cell culture and R. parkeri infections. Confluent low-passage-number African green monkey
epithelial Vero cells were obtained from the University of California Berkeley Cell Culture Facility and
grown at 37°C in 5% CO2 and in high-glucose (4.5 g/liter) Dulbecco’s modified Eagle’s medium (DMEM)
(11965092; Gibco/Life Technologies) supplemented with 2% fetal bovine serum (FBS; Benchmark). R.
parkeri strain Portsmouth was generously provided by Chris Paddock (Centers for Disease Control and
Prevention). R. parkeri was propagated by infecting monolayers of Vero cells with wild-type R. parkeri at
a multiplicity of infection (MOI) of 0.1 and growing them at 33°C in 5% CO2 in DMEM plus 2% FBS.
Bacteria were purified from infected cells as described previously (56). Briefly, infected cells were lysed
by Dounce homogenization in cold K-36 buffer (0.05 M KH2PO4, 0.05 M K2HPO4, pH 7, 100 mM KCl, 15 mM
NaCl) to release bacteria; the lysate was overlaid onto 30% MD-76R (1317-07; Mallinckrodt, Inc. ),
centrifuged at 58,300 g for 20 min at 4°C in an SW-28 swinging bucket rotor, and resuspended in cold
brain heart infusion (BHI) broth (237500; BD Difco) Aliquots of bacteria were immediately frozen at –80°C
after purification, and each infection was initiated from a single thawed aliquot of bacteria.
Rickettsiales pathway analyses, idi locus mapping, and whole-genome alignments. Cladogram
schema were manually drawn based on relative distances from a previous phylogeny study of small
subunit rRNA genes from the order Rickettsiales (57). The presence/absence of the MEP pathway or idi
gene was determined using the KEGG pathway database (http://www.kegg.jp/) and manual annotations
of the terpenoid backbone biosynthesis pathway (http://www.kegg.jp/kegg-bin/show_pathway?map
map00900) for each bacterial species. Determination of intracellular niche was performed by manual
literature curation. The idi locus map and annotations were examined using Geneious software, version
9.1.8, using the R. parkeri strain Portsmouth genome sequence (NCBI RefSeq NC_017044.1). Whole-
genome alignments of R. parkeri strain Portsmouth and R. rickettsii strain Iowa (NCBI RefSeq
NC_010263.3) were performed using the Mauve, version 2.3.1 (58), plug-in in Geneious software using
the progressive Mauve algorithm with automatically calculated-minimum locally colinear block (LCBs)
scores.
Mass spectrometry.Monolayers of uninfected control Vero cells or Vero cells infected with R. parkeri
were plated in six-well plates as described above and were incubated for 4 days at a 33°C in 5% CO2. On
the day of harvest, cells in each well were washed with 4 ml of 1 phosphate-buffered saline (PBS). One
milliliter of fresh 1 PBS was added to each well and used to scrape the cells, samples were centrifuged
at 1,000 g for 5 min on a microcentrifuge, and the supernatant was aspirated from the cell pellet. Cell
pellets were extracted in 2:1:1 chloroform-methanol-PBS solution with addition of 10 nM dodecyl
glycerol internal standard, after which the organic phase was separated, collected, and dried down under
N2 gas. The dried-down lipidome extract was then resuspended in 150 l of chloroform and stored at
80°C until analysis. For mass spectrometry analysis, an aliquot of this sample solution was injected into
an Agilent 6430 LC-MS/MS instrument and was analyzed by single-reaction monitoring (SRM)-based
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targeted LC-MS/MS. Metabolite separation was performed using reverse phase chromatography, using a
Luna reverse phase C5 column (50 mm by 4.6 mm with 5-m diameter particles; Phenomenex), using the
following mobile phases: buffer A consisting of 95:5 water-methanol and buffer B consisting of 60:35:5
2-propanol–methanol–water, both with 0.1% formic acid and 50 mM ammonium formate additives. The
flow rate began at 0.1 ml/min for 5 min, followed by a gradient starting at 0% buffer B and increasing
linearly to 100% buffer B over the course of 40 min with a flow rate of 0.4 ml/min, followed by an isocratic
gradient of 100% buffer B for 10 min before equilibration for 5 min at 0% buffer B with a flow rate of
0.4 ml/min. MS analysis was performed using electrospray ionization (ESI) with a drying gas temperature
of 350°C, drying gas flow rate of 10 liters/min, nebulizer pressure of 35 lb/in2, capillary voltage of 3.0 kV,
and fragmentor voltage of 100 V.
C55-P and C55-PP levels were measured based on targeting for the parent [M-H] mass since there
were no authentic standards available. The retention times for these metabolites correspond with the
expected retention times based on those of shorter-chain pyrophosphate metabolites. For cholesterol,
cholesteryl ester totals, cholesteryl oleate, and ubiquinone-10/8, we used single-reaction monitoring
(SRM)-based methods monitoring the MS1-to-MS2 transitions based on fragmentation of standards.
C55-P and C55-PP were measured in negative ionization mode, whereas cholesterol, total cholesteryl
esters, cholesteryl oleate, and ubiquinone-10/8 were measured in positive ionization mode. Represen-
tative metabolites were quantified by SRM of the transitions from precursor to product ions at associated
collision energies and retention times. Data were analyzed using Agilent Qualitative Analysis software by
calculating the area under the curve (21, 22), and values are in picomoles relative to the internal standard
control equivalents.
Microscopy. To measure bacterial shape, Vero cells were plated at 50% confluence on 96-well
glass-bottom plates in DMEM plus 2% FBS and allowed to settle overnight at 37°C in 5% CO2. The
following day, cells were infected at an MOI of 0.1 of wild-type R. parkeri, centrifuged at 300 g for 5 min,
and incubated for 2 h at 33°C in 5% CO2. Medium containing bacteria was aspirated and replaced with
medium with or without the appropriate concentration of drug (see above), and cells were further
incubated for 72 h at 33°C in 5% CO2. Cells were fixed with 4% paraformaldehyde in 1 PBS for 20 min
at room temperature, washed with 1 PBS, and permeabilized with 0.05% Triton X-100 in 1 PBS for
5 min. Cells were then stained for immunofluorescence with mouse anti-Rickettsia primary antibody
14-13 and goat anti-mouse Alexa-488 secondary antibody to stain bacteria and Hoechst 33342 to stain
DNA. Infected cells were imaged on a Nikon Ti Eclipse microscope with a Yokogawa CSU-XI spinning disc
confocal, 100 (1.4 numerical aperture [NA]) plan apo objective, a Clara Interline charge-coupled-device
(CCD) camera, and MetaMorph software taking 0.15-m z-slices across 5 m in the z-plane. Maximum
z-projections for each channel were made using ImageJ, and a custom pipeline was created in CellProfiler
software (35) to identify individual bacteria in each image. The CellProfiler module MeasureObjectSize-
Shape was used to calculate size and shape parameters of each bacterium. Bright-field monolayer images
were acquired using an Olympus IX71 microscope equipped with a 20 LUCPlanFLN objective and a
Photometrics CoolSnap HQ camera and MicroManager software.
R. parkeri qPCR growth and drug dose-response curves. Confluent Vero cells grown in 96-well
tissue culture plates were infected with R. parkeri at an MOI of 0.1 and incubated in DMEM plus 2% FBS
with or without the appropriate concentration of drug (see above) for 72 h at 33°C in 5% CO2. To harvest
cells at the appropriate time point, medium was aspirated, and cells were lifted with 50 l of 0.25%
trypsin-EDTA followed by incubation at 37°C for 5 min. Lifted cells were resuspended with an additional
50 l of DMEM before being added to 50 l of Nuclei Lysis Solution (Wizard Genomic DNA Purification
kit; Promega) and frozen at 20°C overnight. Cells were then thawed and boiled for 10 min to release
genomic DNA. To remove RNA, 20 g/ml RNase A was added to each sample, and samples were
incubated for 15 min at 37°C and then cooled to room temperature. Protein was removed by addition
of 50 l of protein precipitation solution, mixed by pipetting, and then centrifuged in a microcentrifuge
for 15 min at 1,500 g at 4°C. DNA was precipitated by addition of 100 l of the resulting supernatant
to 100 l of isopropanol, mixed by pipetting, and centrifuged for 15 min at 1,500 g at 4°C. Isopropanol
was removed, and the DNA pellet was washed with 70% ethanol and centrifuged for 15 min at 1,500 g.
Resulting DNA pellets were dried, resuspended in 50 l of H2O, and allowed to rehydrate overnight at
4°C. For quantitative real-time PCR, 5 l of genomic DNA was used with primers to the R. parkeri gene
encoding the 17-kDa antigen (59), and runs were carried out on a Bio-Rad CFX96 Touch real-time PCR
detection system. Rickettsia genome copy number was quantified against a standard curve of a plasmid
containing a single copy of the R. parkeri 17-kDa gene. Regression analysis and EC50 calculations were
performed using GraphPad Prism, version 7, software.
LDH release assays. For lactate dehydrogenase (LDH) release assays, Vero cells were plated and
grown to confluence in a 96-well plate in 100 l of DMEM (Gibco) containing 2% FBS (GemCell). The
following day, medium was aspirated and replaced with 100 l of fresh medium containing pitavastatin
or lovastatin and incubated at 33°C. After 72 h, 60 l of supernatant from wells containing Vero cells was
collected into 96-well plates and 60 l of LDH buffer (3 l of diaphorase [DIA] solution containing 13.5
units/ml DIA [D5540; Sigma], 3 mg/ml -nicotinamide adenine dinucleotide hydrate [N3014; Sigma],
0.03% bovine serum albumin [BSA], and 1.2% sucrose; 3 l of INT solution, containing 2 mg/ml tetrazo-
lium salt [I8377; Sigma] in PBS; 34 l of PBS with 0.5% BSA; and 20 l of solution containing 36 mg/ml
lithium lactate in 10 mM Tris-HCl, pH 8.5 [L2250; Sigma ]) was added to each well. Supernatants from
untreated cells and from cells lysed with 1% Triton X-100 were used as controls. Reaction mixtures were
incubated at room temperature for 20 min prior to reading the absorbance at 490 nm using an Infinite
F200 Pro plate reader (Tecan). Values for untreated Vero cells were subtracted from the experimental
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values, divided by the difference of Triton-lysed and untreated cells, and multiplied by 100 to obtain
percent lysis. Each experiment was performed, and data were averaged between biological triplicates.
Statistical analyses. Statistical analysis was performed in GraphPad Prism, version 7, and statistical
parameters and significance are reported in the figures and figure legends. Statistical significance was
determined either by an unpaired Student’s t test or a one-way analysis of variance (ANOVA) where
indicated in the figure legends.
Data availability. Raw mass spectrometry data can be accessed at https://www.ebi.ac.uk/
metabolights/MTBLS846.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSphere.00536-19.
FIG S1, PDF file, 2.3 MB.
TABLE S1, PDF file, 0.03 MB.
TABLE S2, PDF file, 0.02 MB.
ACKNOWLEDGMENTS
We are grateful to Rebecca Lamason for critical reading of the manuscript. We thank
Eric Lee and Dan Portnoy for reagents. We thank Matthew Knight, Eric Lee, Ellen Yeh,
David Booth, Thibaut Brunet, and members of the Welch lab for helpful technical advice
and discussions.
This work was performed in part at the Cancer Research Lab Molecular Imaging
Center, which is supported by NIH grant S10RR027696. V.A. was supported by NIH/
NIAID grant F32 AI133912. M.D.W. was supported by NIH/NIAID grants R01 AI109044
and R21 AI109270. C.A.B. and D.K.N. were supported by NIH/NCI grant R01 CA172667.
REFERENCES
1. Yu X-J, Walker DH. 2006. The order Rickettsiales, p 493–528. In Dworkin
M, Falkow S, Rosenberg E, Schleifer KH, Stackebrandt E (ed), The Pro-
karyotes. Springer, New York, NY.
2. Kirkland KB, Wilkinson WE, Sexton DJ. 1995. Therapeutic delay and
mortality in cases of Rocky Mountain spotted fever. Clin Infect Dis
20:1118–1121. https://doi.org/10.1093/clinids/20.5.1118.
3. Paddock CD, Sumner JW, Comer JA, Zaki SR, Goldsmith CS, Goddard J,
McLellan SLF, Tamminga CL, Ohl CA. 2004. Rickettsia parkeri: a newly
recognized cause of spotted fever rickettsiosis in the United States. Clin
Infect Dis 38:805–811. https://doi.org/10.1086/381894.
4. Paddock CD, Finley RW, Wright CS, Robinson HN, Schrodt BJ, Lane CC,
Ekenna O, Blass MA, Tamminga CL, Ohl CA, McLellan SLF, Goddard J,
Holman RC, Openshaw JJ, Sumner JW, Zaki SR, Eremeeva ME. 2008.
Rickettsia parkeri rickettsiosis and its clinical distinction from Rocky
Mountain spotted fever. Clin Infect Dis 47:1188–1196. https://doi.org/
10.1086/592254.
5. Andersson JO, Andersson SG. 1999. Insights into the evolutionary pro-
cess of genome degradation. Curr Opin Genet Dev 9:664–671. https://
doi.org/10.1016/s0959-437x(99)00024-6.
6. Moran NA. 2002. Microbial minimalism: genome reduction in bacterial
pathogens. Cell 108:583–586. https://doi.org/10.1016/s0092-8674(02)
00665-7.
7. Darby AC, Cho N-H, Fuxelius H-H, Westberg J, Andersson S. 2007.
Intracellular pathogens go extreme: genome evolution in the Rickettsia-
les. Trends Genet 23:511–520. https://doi.org/10.1016/j.tig.2007.08.002.
8. Blanc G, Ogata H, Robert C, Audic S, Suhre K, Vestris G, Claverie J-M,
Raoult D. 2007. Reductive genome evolution from the mother of Rick-
ettsia. PLoS Genet 3:e14. https://doi.org/10.1371/journal.pgen.0030014.
9. Gillespie JJ, Williams K, Shukla M, Snyder EE, Nordberg EK, Ceraul SM,
Dharmanolla C, Rainey D, Soneja J, Shallom JM, Vishnubhat ND, Wattam
R, Purkayastha A, Czar M, Crasta O, Setubal JC, Azad AF, Sobral BS.
2008. Rickettsia phylogenomics: unwinding the intricacies of obligate
intracellular life. PLoS One 3:e2018. https://doi.org/10.1371/journal
.pone.0002018.
10. Heuston S, Begley M, Gahan CGM, Hill C. 2012. Isoprenoid biosynthesis
in bacterial pathogens. Microbiology 158:1389–1401. https://doi.org/10
.1099/mic.0.051599-0.
11. Goldstein JL, Brown MS. 1990. Regulation of the mevalonate pathway.
Nature 343:425–430. https://doi.org/10.1038/343425a0.
12. Eberl M, Hintz M, Jamba Z, Beck E, Jomaa H, Christiansen G. 2004.
Mycoplasma penetrans is capable of activating V9/V2 T cells while
other human pathogenic mycoplasmas fail to do so. Infect Immun
72:4881–4883. https://doi.org/10.1128/IAI.72.8.4881-4883.2004.
13. Clastre M, Goubard A, Prel A, Mincheva Z, Viaud-Massuart M-C, Bout D,
Rideau M, Velge-Roussel F, Laurent F. 2007. The methylerythritol phos-
phate pathway for isoprenoid biosynthesis in coccidia: presence and
sensitivity to fosmidomycin. Exp Parasitol 116:375–384. https://doi.org/
10.1016/j.exppara.2007.02.002.
14. Driscoll TP, Verhoeve VI, Guillotte ML, Lehman SS, Rennoll SA, Beier-
Sexton M, Rahman MS, Azad AF, Gillespie JJ. 2017. Wholly Rickettsia!
Reconstructed metabolic profile of the quintessential bacterial para-
site of eukaryotic cells. mBio 8:e00859-17. https://doi.org/10.1128/
mBio.00859-17.
15. Berthelot K, Estevez Y, Deffieux A, Peruch F. 2012. Isopentenyl diphos-
phate isomerase: a checkpoint to isoprenoid biosynthesis. Biochimie
94:1621–1634. https://doi.org/10.1016/j.biochi.2012.03.021.
16. Hagen R, Verhoeve VI, Gillespie JJ, Driscoll TP. 2018. Conjugative trans-
posons and their cargo genes vary across natural populations of Rick-
ettsia buchneri infecting the tick Ixodes scapularis. Genome Biol Evol
10:3218–3229. https://doi.org/10.1093/gbe/evy247.
17. Murphy DJ. 2001. The biogenesis and functions of lipid bodies in
animals, plants and microorganisms. Prog Lipid Res 40:325–438. https://
doi.org/10.1016/S0163-7827(01)00013-3.
18. Manat G, Roure S, Auger R, Bouhss A, Barreteau H, Mengin-Lecreulx D,
Touzé T. 2014. Deciphering the metabolism of undecaprenyl-phosphate:
the bacterial cell-wall unit carrier at the membrane frontier. Microb Drug
Resist 20:199–214. https://doi.org/10.1089/mdr.2014.0035.
19. Nowicka B, Kruk J. 2010. Occurrence, biosynthesis and function of
isoprenoid quinones. Biochim Biophys Acta 1797:1587–1605. https://doi
.org/10.1016/j.bbabio.2010.06.007.
20. Aussel L, Pierrel F, Loiseau L, Lombard M, Fontecave M, Barras F. 2014.
Biosynthesis and physiology of coenzyme Q in bacteria. Biochim Biophys
Acta 1837:1004–1011. https://doi.org/10.1016/j.bbabio.2014.01.015.
21. Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Mulvihill MM, Luo K,
Nomura DK. 2013. Ether lipid generating enzyme AGPS alters the bal-
ance of structural and signaling lipids to fuel cancer pathogenicity. Proc
Natl Acad Sci U S A 110:14912–14917. https://doi.org/10.1073/pnas
.1310894110.
22. Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR,
Miyamoto DK, Goga A, Weerapana E, Nomura DK. 2016. GSTP1 is a driver
Rickettsia Parasitism of Host Isoprenoids
November/December 2019 Volume 4 Issue 6 e00536-19 msphere.asm.org 13
of triple-negative breast cancer cell metabolism and pathogenicity. Cell
Chem Biol 23:567–578. https://doi.org/10.1016/j.chembiol.2016.03.017.
23. Botelho-Nevers E, Rolain JM, Espinosa L, Raoult D. 2008. Statins limit
Rickettsia conorii infection in cells. Int J Antimicrob Agents 32:344–348.
https://doi.org/10.1016/j.ijantimicag.2008.04.027.
24. Reed SCO, Serio AW, Welch MD. 2012. Rickettsia parkeri invasion of
diverse host cells involves an Arp2/3 complex, WAVE complex and
Rho-family GTPase-dependent pathway. Cell Microbiol 14:529–545.
https://doi.org/10.1111/j.1462-5822.2011.01739.x.
25. Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati IS, Fogal V, Pastorino
S, Teng D, Cong X, Pingle SC, Kapoor S, Shetty K, Aggrawal A, Vali S,
Abbasi T, Chien S, Kesari S. 2014. In vitro and in vivo anticancer effects
of mevalonate pathway modulation on human cancer cells. Br J Cancer
111:1562–1571. https://doi.org/10.1038/bjc.2014.431.
26. Zhao W, Zhao S-P. 2015. Different effects of statins on induction of
diabetes mellitus: an experimental study. Drug Des Devel Ther
9:6211–6223. https://doi.org/10.2147/DDDT.S87979.
27. Tsujimoto A, Takemura G, Mikami A, Aoyama T, Ohno T, Maruyama R,
Nakagawa M, Minatoguchi S, Fujiwara H. 2006. A therapeutic dose of the
lipophilic statin pitavastatin enhances oxidant-induced apoptosis in hu-
man vascular smooth muscle cells. J Cardiovasc Pharmacol 48:160–165.
https://doi.org/10.1097/01.fjc.0000245989.89771.1b.
28. Rolain JM, Maurin M, Vestris G, Raoult D. 1998. In vitro susceptibilities of
27 rickettsiae to 13 antimicrobials. Antimicrob Agents Chemother 42:
1537–1541. https://doi.org/10.1128/AAC.42.7.1537.
29. Pang H, Winkler HH. 1994. Analysis of the peptidoglycan of Rickettsia
prowazekii. J Bacteriol 176:923–926. https://doi.org/10.1128/jb.176.3.923
-926.1994.
30. Baisa G, Stabo NJ, Welch RA. 2013. Characterization of Escherichia coli
D-cycloserine transport and resistant mutants. J Bacteriol 195:
1389–1399. https://doi.org/10.1128/JB.01598-12.
31. Desjardins CA, Cohen KA, Munsamy V, Abeel T, Maharaj K, Walker BJ,
Shea TP, Almeida DV, Manson AL, Salazar A, Padayatchi N, O’Donnell MR,
Mlisana KP, Wortman J, Birren BW, Grosset J, Earl AM, Pym AS. 2016.
Genomic and functional analyses of Mycobacterium tuberculosis strains
implicate ald in D-cycloserine resistance. Nat Genet 48:544–551. https://
doi.org/10.1038/ng.3548.
32. Delcour AH. 2009. Outer membrane permeability and antibiotic resis-
tance. Biochim Biophys Acta 1794:808–816. https://doi.org/10.1016/j
.bbapap.2008.11.005.
33. Wisseman CL, Silverman DJ, Waddell A, Brown DT. 1982. Penicillin-
induced unstable intracellular formation of spheroplasts by rickettsiae. J
Infect Dis 146:147–158. https://doi.org/10.1093/infdis/146.2.147.
34. Allan EJ, Hoischen C, Gumpert J. 2009. Bacterial L-forms. Adv Appl
Microbiol 68:1–39. https://doi.org/10.1016/S0065-2164(09)01201-5.
35. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O,
Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM.
2006. CellProfiler: image analysis software for identifying and quantify-
ing cell phenotypes. Genome Biol 7:R100. https://doi.org/10.1186/gb
-2006-7-10-r100.
36. Wolf YI, Koonin EV. 2013. Genome reduction as the dominant mode of
evolution. Bioessays 35:829–837. https://doi.org/10.1002/bies.201300037.
37. Bick JA, Lange BM. 2003. Metabolic cross talk between cytosolic and plas-
tidial pathways of isoprenoid biosynthesis: unidirectional transport of inter-
mediates across the chloroplast envelope membrane. Arch Biochem Bio-
phys 415:146–154. https://doi.org/10.1016/s0003-9861(03)00233-9.
38. Flügge U-I, Gao W. 2005. Transport of isoprenoid intermediates across
chloroplast envelope membranes. Plant Biol (Stuttg) 7:91–97. https://doi
.org/10.1055/s-2004-830446.
39. Yeh E, DeRisi JL. 2011. Chemical rescue of malaria parasites lacking an
apicoplast defines organelle function in blood-stage Plasmodium falci-
parum. PLoS Biol 9:e1001138. https://doi.org/10.1371/journal.pbio.1001138.
40. Frohlich KM, Roberts RAW, Housley NA, Audia JP. 2010. Rickettsia prowa-
zekii uses an sn-glycerol-3-phosphate dehydrogenase and a novel dihy-
droxyacetone phosphate transport system to supply triose phosphate
for phospholipid biosynthesis. J Bacteriol 192:4281–4288. https://doi
.org/10.1128/JB.00443-10.
41. Frohlich KM, Audia JP. 2013. Dual mechanisms of metabolite acquisition
by the obligate intracytosolic pathogen Rickettsia prowazekii reveal
novel aspects of triose phosphate transport. J Bacteriol 195:3752–3760.
https://doi.org/10.1128/JB.00404-13.
42. Carabeo RA, Mead DJ, Hackstadt T. 2003. Golgi-dependent transport of
cholesterol to the Chlamydia trachomatis inclusion. Proc Natl Acad Sci
U S A 100:6771–6776. https://doi.org/10.1073/pnas.1131289100.
43. Samanta D, Mulye M, Clemente TM, Justis AV, Gilk SD. 2017. Manipula-
tion of host cholesterol by obligate intracellular bacteria. Front Cell
Infect Microbiol 7:165. https://doi.org/10.3389/fcimb.2017.00165.
44. Wilburn KM, Fieweger RA, VanderVen BC. 2018. Cholesterol and fatty
acids grease the wheels of Mycobacterium tuberculosis pathogenesis.
Pathog Dis 76:fty021. https://doi.org/10.1093/femspd/fty021.
45. Ramm LE, Winkler HH. 1976. Identification of cholesterol in the receptor
site for rickettsiae on sheep erythrocyte membranes. Infect Immun
13:120–126.
46. Martinez JJ, Seveau S, Veiga E, Matsuyama S, Cossart P. 2005. Ku70, a
component of DNA-dependent protein kinase, is a mammalian receptor
for Rickettsia conorii. Cell 123:1013–1023. https://doi.org/10.1016/j.cell
.2005.08.046.
47. Strickman D, Sheer T, Salata K, Hershey J, Dasch G, Kelly D, Kuschner R.
1995. In vitro effectiveness of azithromycin against doxycycline-resistant
and -susceptible strains of Rickettsia tsutsugamushi, etiologic agent of
scrub typhus. Antimicrob Agents Chemother 39:2406–2410. https://doi
.org/10.1128/aac.39.11.2406.
48. Kelly DJ, Fuerst PA, Richards AL. 2017. The historical case for and the
future study of antibiotic-resistant scrub typhus. Tropical Med Infect Dis
2:63. https://doi.org/10.3390/tropicalmed2040063.
49. Cross R, Ling C, Day NPJ, McGready R, Paris DH. 2016. Revisiting doxy-
cycline in pregnancy and early childhood–time to rebuild its reputa-
tion? Expert Opin Drug Saf 15:367–382. 29 ed. https://doi.org/10.1517/
14740338.2016.1133584.
50. Karalis DG, Hill AN, Clifton S, Wild RA. 2016. The risks of statin use in
pregnancy: a systematic review. J Clin Lipidol 10:1081–1090. https://doi
.org/10.1016/j.jacl.2016.07.002.
51. Braamskamp M, Stefanutti C, Langslet G, Drogari E, Wiegman A, Houn-
slow N, Kastelein JJP, PASCAL Study Group. 2015. Efficacy and safety of
pitavastatin in children and adolescents at high future cardiovascular
risk. J Pediatr 167:338–343.e5. https://doi.org/10.1016/j.jpeds.2015
.05.006.
52. Bessoff K, Sateriale A, Lee KK, Huston CD. 2013. Drug repurposing screen
reveals FDA-approved inhibitors of human HMG-CoA reductase and
isoprenoid synthesis that block Cryptosporidium parvum growth. Anti-
microb Agents Chemother 57:1804–1814. https://doi.org/10.1128/AAC
.02460-12.
53. Li Z-H, Ramakrishnan S, Striepen B, Moreno S. 2013. Toxoplasma gondii
relies on both host and parasite isoprenoids and can be rendered
sensitive to atorvastatin. PLoS Pathog 9:e1003665. https://doi.org/10
.1371/journal.ppat.1003665.
54. Li Z-H, Li C, Szajnman SH, Rodriguez JB, Moreno S. 2017. Synergistic
activity between statins and bisphosphonates against acute experimen-
tal toxoplasmosis. Antimicrob Agents Chemother 61:e02628-16. https://
doi.org/10.1128/AAC.02628-16.
55. Anacker RL, Mann RE, Gonzales C. 1987. Reactivity of monoclonal anti-
bodies to Rickettsia rickettsii with spotted fever and typhus group rick-
ettsiae. J Clin Microbiol 25:167–171.
56. Lamason RL, Bastounis E, Kafai NM, Serrano R, Del Álamo JC, Theriot JA,
Welch MD. 2016. Rickettsia Sca4 reduces vinculin-mediated intercellular
tension to promote spread. Cell 167:670–683.e10. https://doi.org/10
.1016/j.cell.2016.09.023.
57. Driscoll T, Gillespie JJ, Nordberg EK, Azad AF, Sobral BW. 2013. Bacterial
DNA sifted from the Trichoplax adhaerens (Animalia: Placozoa) genome
project reveals a putative rickettsial endosymbiont. Genome Biol Evol
5:621–645. https://doi.org/10.1093/gbe/evt036.
58. Darling AE, Mau B, Perna NT. 2010. progressiveMauve: multiple genome
alignment with gene gain, loss and rearrangement. PLoS One 5:e11147.
https://doi.org/10.1371/journal.pone.0011147.
59. Grasperge BJ, Reif KE, Morgan TD, Sunyakumthorn P, Bynog J, Paddock
CD, Macaluso KR. 2012. Susceptibility of inbred mice to Rickettsia parkeri.
Infect Immun 80:1846–1852. https://doi.org/10.1128/IAI.00109-12.
Ahyong et al.
November/December 2019 Volume 4 Issue 6 e00536-19 msphere.asm.org 14
